$APVO
Aptevo Therapeutics Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022019685 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $3.114M $2.421M
YoY Change 28.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.859M $3.950M
YoY Change -2.3% 9.12%
% of Gross Profit
Research & Development $4.866M $5.360M
YoY Change -9.22% 33.67%
% of Gross Profit
Depreciation & Amortization $242.0K $294.0K
YoY Change -17.69% -36.09%
% of Gross Profit
Operating Expenses $8.725M $9.310M
YoY Change -6.28% 22.15%
Operating Profit -$5.611M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.264M -$780.0K
YoY Change 190.26% 183.64%
Pretax Income -$7.875M -$7.670M
YoY Change 2.67% -23.3%
Income Tax
% Of Pretax Income
Net Earnings -$7.697M -$7.256M
YoY Change 6.08% -350.47%
Net Earnings / Revenue -247.17% -299.71%
Basic Earnings Per Share -$1.55
Diluted Earnings Per Share -$1.559M -$1.643M
COMMON SHARES
Basic Shares Outstanding 4.937M 4.449M
Diluted Shares Outstanding 4.937M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.99M $57.50M
YoY Change -39.15% 367.48%
Cash & Equivalents $36.25M $58.78M
Short-Term Investments
Other Short-Term Assets $3.567M $2.900M
YoY Change 23.0% 136.93%
Inventory
Prepaid Expenses
Receivables $3.114M $2.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $41.67M $62.90M
YoY Change -33.75% 324.28%
LONG-TERM ASSETS
Property, Plant & Equipment $3.444M $2.712M
YoY Change 26.99% -61.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $68.00K $746.0K
YoY Change -90.88% -77.39%
Total Long-Term Assets $3.512M $5.853M
YoY Change -40.0% -43.59%
TOTAL ASSETS
Total Short-Term Assets $41.67M $62.90M
Total Long-Term Assets $3.512M $5.853M
Total Assets $45.18M $68.75M
YoY Change -34.28% 172.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.910M $5.400M
YoY Change -27.59% 8.0%
Accrued Expenses $2.140M $1.100M
YoY Change 94.55% -35.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $10.17M
YoY Change -80.33%
Total Short-Term Liabilities $23.86M $29.30M
YoY Change -18.58% 318.99%
LONG-TERM LIABILITIES
Long-Term Debt $2.804M $4.600M
YoY Change -39.04%
Other Long-Term Liabilities $24.41M $24.30M
YoY Change 0.44% 683.87%
Total Long-Term Liabilities $27.21M $28.90M
YoY Change -5.84% 832.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.86M $29.30M
Total Long-Term Liabilities $27.21M $28.90M
Total Liabilities $51.07M $58.25M
YoY Change -12.33% 476.72%
SHAREHOLDERS EQUITY
Retained Earnings -$192.9M
YoY Change
Common Stock $203.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.884M $10.50M
YoY Change
Total Liabilities & Shareholders Equity $45.18M $68.75M
YoY Change -34.28% 172.83%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$7.697M -$7.256M
YoY Change 6.08% -350.47%
Depreciation, Depletion And Amortization $242.0K $294.0K
YoY Change -17.69% -36.09%
Cash From Operating Activities -$5.117M -$7.504M
YoY Change -31.81% -32.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $191.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$191.0K
YoY Change -100.0% -100.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $10.77M $5.000M
YoY Change 115.34% -77.38%
Cash From Financing Activities -4.936M 23.94M
YoY Change -120.62% -208.32%
NET CHANGE
Cash From Operating Activities -5.117M -7.504M
Cash From Investing Activities 0.000 -191.0K
Cash From Financing Activities -4.936M 23.94M
Net Change In Cash -5.117M 16.25M
YoY Change -131.5% -414.93%
FREE CASH FLOW
Cash From Operating Activities -$5.117M -$7.504M
Capital Expenditures $0.00 $191.0K
Free Cash Flow -$5.117M -$7.695M
YoY Change -33.5% -31.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
CY2022Q1 apvo Liabilities Held For Sale Current
LiabilitiesHeldForSaleCurrent
15318000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1040000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68000
CY2022Q1 us-gaap Assets
Assets
45184000
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3910000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7256000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
294000
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.74
CY2021Q4 apvo Liabilities Held For Sale Non Current
LiabilitiesHeldForSaleNonCurrent
15580000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
3707000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1341000
CY2021Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7670000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
414000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.09
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4418472
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7256000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
574000
CY2022Q1 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
CY2022Q1 apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-550000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5117000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-191000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10767000
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10550000
CY2022Q1 apvo Repayments Under Liability Related To Sale Of Royalties
RepaymentsUnderLiabilityRelatedToSaleOfRoyalties
3665000
CY2021Q1 apvo Proceeds From Sale Of Royalties
ProceedsFromSaleOfRoyalties
35000000
CY2021Q1 apvo Transaction Costs From Sale Of Royalties
TransactionCostsFromSaleOfRoyalties
1100000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
CY2022Q1 apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
4000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
506000
CY2022Q1 apvo Proceeds From Milestones Related To Sale Of Royalties
ProceedsFromMilestonesRelatedToSaleOfRoyalties
10000000
CY2022Q1 apvo Transaction Costs For Milestones Related To Sale Of Royalties
TransactionCostsForMilestonesRelatedToSaleOfRoyalties
500000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23942000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16247000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58781000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1216000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7697000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5884000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16594000
CY2021Q1 apvo Proceeds From Exercise Of Stock Options Value
ProceedsFromExerciseOfStockOptionsValue
-86000
CY2021Q1 apvo Proceeds From Exercise Of Warrants Value
ProceedsFromExerciseOfWarrantsValue
-506000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
574000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7256000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10504000
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000
CY2022Q1 apvo Milestone Payment
MilestonePayment
10000000
CY2021Q1 apvo Payment Of Royalty Purchase Agreement Percentage
PaymentOfRoyaltyPurchaseAgreementPercentage
1.90
CY2021Q1 apvo Payment Of Royalty Interest Percentage
PaymentOfRoyaltyInterestPercentage
0.50
CY2021Q1 apvo Discontinued Operating Gain On Contingent Consideration
DiscontinuedOperatingGainOnContingentConsideration
227000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
900000
CY2022Q1 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
178000
CY2021Q1 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
187000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
178000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
414000
CY2022Q1 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
200000
CY2021Q1 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
100000
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
32000000.0
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
41200000
CY2022Q1 apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2022Q1 us-gaap Cash
Cash
2986000
CY2021Q4 us-gaap Cash
Cash
3841000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
32005000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
41203000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46303000
CY2021Q1 apvo Payment Of Amount Outstanding
PaymentOfAmountOutstanding
10000000.0
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5000000.0
CY2021Q1 apvo Amendment Fees
AmendmentFees
600000
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000.0
CY2022Q1 apvo Milestone Payment
MilestonePayment
10000000.0
CY2022Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.230
CY2021Q4 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
31045000
CY2021Q1 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
35000000
CY2021Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1100000
CY2022Q1 apvo Milestone Payment Received Net Of Transaction Costs
MilestonePaymentReceivedNetOfTransactionCosts
9500000
CY2022Q1 apvo Non Cash Interest Expense
NonCashInterestExpense
1780000
CY2021Q1 apvo Non Cash Interest Expense
NonCashInterestExpense
20000
CY2022Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
3665000
CY2022Q1 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
38660000
CY2021Q1 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
33920000
CY2022Q1 apvo Liability Related To Sale Of Royalties Current
LiabilityRelatedToSaleOfRoyaltiesCurrent
-15318000
CY2021Q1 apvo Liability Related To Sale Of Royalties Current
LiabilityRelatedToSaleOfRoyaltiesCurrent
-11748000
CY2022Q1 apvo Liability Related To Sale Of Royalties Non Current
LiabilityRelatedToSaleOfRoyaltiesNonCurrent
23342000
CY2021Q1 apvo Liability Related To Sale Of Royalties Non Current
LiabilityRelatedToSaleOfRoyaltiesNonCurrent
22172000
CY2022Q1 apvo Operating Lease Property Number Of Lab Equipment
OperatingLeasePropertyNumberOfLabEquipment
1
CY2022Q1 apvo Operating Lease Property Number Of Copiers
OperatingLeasePropertyNumberOfCopiers
4
CY2022Q1 apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
1
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
300000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
360000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
395000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2022Q1 us-gaap Lease Cost
LeaseCost
362000
CY2021Q1 us-gaap Lease Cost
LeaseCost
397000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1307000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1584000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
323000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
346000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1100000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y29D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1445
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y18D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1450
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7875000
CY2021Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7670000
CY2022Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
178000
CY2021Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
414000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7697000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7256000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.59
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.74
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.04
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.09
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.55
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4937456
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4418472
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
200000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
601000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31986
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
292
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.43
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.09
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.20
CY2021Q1 apvo Number Of Common Stock Shares To Be Issued Upon Exercise Of Warrants
NumberOfCommonStockSharesToBeIssuedUponExerciseOfWarrants
27828
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
500000

Files In Submission

Name View Source Status
0001564590-22-019685-index-headers.html Edgar Link pending
0001564590-22-019685-index.html Edgar Link pending
0001564590-22-019685.txt Edgar Link pending
0001564590-22-019685-xbrl.zip Edgar Link pending
apvo-10q_20220331.htm Edgar Link pending
apvo-10q_20220331_htm.xml Edgar Link completed
apvo-20220331.xsd Edgar Link pending
apvo-20220331_cal.xml Edgar Link unprocessable
apvo-20220331_def.xml Edgar Link unprocessable
apvo-20220331_lab.xml Edgar Link unprocessable
apvo-20220331_pre.xml Edgar Link unprocessable
apvo-ex311_8.htm Edgar Link pending
apvo-ex312_9.htm Edgar Link pending
apvo-ex321_10.htm Edgar Link pending
apvo-ex322_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending